Information Hub

Clinical News

2020-09-22

Olaparib and Durvalumab Combination Showed Promising Results in HER2-negative Breast Cancer Patients with Germline BRCA Mutation

MEDIOLA is a phase I/II basket trial of olaparib and durvalumab. In a study cohort of the MEDIOLA study, the combination of olaparib and durvalumab showed promising anti-tumor activity in HER2-negative gBRCA-mutated breast cancer.

Source:

Lancet Oncol.

2020-09-22

Ensartinib: A new TKI inhibitor prolonged PFS in ALK+ NSCLC patients

In a phase 3 study (eXalt3), ensartinib showed longer mPFS and higher intracranial ORR compared with crizotinib. The results indicated ensartinib can be a new first-line treatment option for patients with ALK+ NSCLC.

Source:

IASLC WCLC 2020

2020-08-21

A new IDH1/2 inhibitor for mutated IDH1/2 low-grade glioma

In a phase I study, the anti-tumor activity of vorasidenib (VOR; AG-881) was demonstrated in mutated IDH1/2 low-grade glioma.

Source:

J Clin Oncol

2020-08-21

A new FGFR inhibitor for intrahepatic cholangiocarcinoma treatment

In a phase 2 study, futibatinib showed anti-tumor efficacy in chemotherapy-treated intrahepatic cholangiocarcinoma with FGFR2 fusion

Source:

J Clin Oncol

2020-08-21

ESR1 Mutation as a Prediction Marker for 1st-line AI plus CDK4/6 Inhibitor in HR+ Breast Cancer Patients

In phase 3 PADA-1 study, HR+ breast cancer patients with an ESR1 mutation showed worse outcomes in response to the 1st-line combination therapy of AI and palbociclib. Moreover, the reduction of plasma ESR1 mutation ctDNA level in the early stage of treatm

Source:

J Clin Oncol

2020-07-22

Capmatinib showed anti-tumor activity in MET-amplified advanced NSCLC

MET amplification is one of the driver genetic alterations in advanced NSCLC. In a phase II study, the anti-tumor activity of capmatinib was demonstrated in treatment-na?ve and pretreated patients with MET-amplified advanced NSCLC.

Source:

J Clin Oncol

2020-07-22

LRP1B pathogenic mutations were associated with clinical benefits on immunotherapy treatment

The immunotherapy-related biomarkers other than PD-L1, MSI-H/dMMR or TMB are still under development. A study analyzed the immunotherapy clinical outcome in cancer patients with LRP1B mutations. The results indicated the LRP1B pathogenic mutations were as

Source:

J Clin Oncol

2020-07-22

Olaparib demonstrates anti-tumor activities in metastatic breast cancer patients harbored a mutation in homologous recombination repair pathway genes

Recently, phase 2 TBCRC 048 study results were published at the 2020 ASCO Virtual Scientific Program. This study aimed to investigate the activities of olaparib in metastatic breast cancer patients who have a homologous recombination repair gene mutation.

Source:

J Clin Oncol

2020-07-08

Is Immunotherapy Right for Me?

Cancer immunotherapy has been hailed as the most promising treatment against cancer in recent decades, but what exactly is immunotherapy? Is Immunotherapy right for me?

Source:

2020-07-07

Merck’s Keytruda grasps FDA approval again with TMB-H biomarker regardless of tumor type

Merck is proficient in the mechanism of immunotherapy, and after Keytruda's first approval in 2017 with MSI-H as biomarker regardless of where in the body cancer started, the same approval came in June 2020 with TMB-H, showing prospects in immunotherapy.

Source:

Fierce Pharma

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草